Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01669876 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate Dietary Supplementation With a Version of Anatabloc(R) in Subjects With Alzheimer's Disease
A Phase 2 study, sponsored by Rock Creek Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 85
- Enrollment target
NCT01669876 is a Phase 2 study that was terminated before completion, run by Rock Creek Pharmaceuticals. The registered enrollment target is 85 participants.
The verdict
NCT01669876, a Phase 2 study, was terminated before completion, sponsored by Rock Creek Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 85 participants
- Enrollment target
Study Summary
To explore whether dietary supplementation with a version of Anatabloc(R) exerts an effect on blood levels of amyloid beta (Aβ), or impacts global or functional measures of Alzheimer's Disease (AD) in subjects with mild to moderate AD.
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT Anatabloc(R)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2012-08 |
| Est. Completion | 2015-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01669876
The ClinicalTrials.gov registry entry for NCT01669876 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rock Creek Pharmaceuticals, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01669876 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01669876 about?
NCT01669876 is a clinical study titled "Study to Evaluate Dietary Supplementation With a Version of Anatabloc(R) in Subjects With Alzheimer's Disease". To explore whether dietary supplementation with a version of Anatabloc(R) exerts an effect on blood levels of amyloid beta (Aβ), or impacts global or functional measures of Alzheimer's Disease (AD) in subjects with mild to moderate AD.
What is the current status of trial NCT01669876?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 85 participants. The study started on 2012-08. Estimated completion is 2015-02.
What interventions are being tested in trial NCT01669876?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Anatabloc(R) (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01669876?
This trial is sponsored by Rock Creek Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.